BR112018071184A2 - inibidores do receptor de activina tipo quinase - Google Patents

inibidores do receptor de activina tipo quinase

Info

Publication number
BR112018071184A2
BR112018071184A2 BR112018071184-5A BR112018071184A BR112018071184A2 BR 112018071184 A2 BR112018071184 A2 BR 112018071184A2 BR 112018071184 A BR112018071184 A BR 112018071184A BR 112018071184 A2 BR112018071184 A2 BR 112018071184A2
Authority
BR
Brazil
Prior art keywords
receptor inhibitors
activin receptor
kinase
kinase activin
compounds
Prior art date
Application number
BR112018071184-5A
Other languages
English (en)
Inventor
Brooijmans Natasja
D. Brubaker Jason
Cronin Mark
E. Fleming Paul
L. Hodous Brian
L. Kim Joseph
Waetzig Josh
Williams Brett
Wilson Douglas
J. Wilson Kevin
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of BR112018071184A2 publication Critical patent/BR112018071184A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

são descritos neste documento compostos que inibem o alk2 e seus mutantes, composições farmacêuticas incluindo esses compostos, e métodos de utilização desses compostos e composições.
BR112018071184-5A 2016-04-15 2017-04-14 inibidores do receptor de activina tipo quinase BR112018071184A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322948P 2016-04-15 2016-04-15
US62/322,948 2016-04-15
US201662411172P 2016-10-21 2016-10-21
US62/411,172 2016-10-21
PCT/US2017/027775 WO2017181117A1 (en) 2016-04-15 2017-04-14 Inhibitors of activin receptor-like kinase

Publications (1)

Publication Number Publication Date
BR112018071184A2 true BR112018071184A2 (pt) 2019-02-12

Family

ID=59215888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071184-5A BR112018071184A2 (pt) 2016-04-15 2017-04-14 inibidores do receptor de activina tipo quinase

Country Status (21)

Country Link
US (3) US10233186B2 (pt)
EP (2) EP4285996A3 (pt)
JP (1) JP7017521B2 (pt)
KR (1) KR102426043B1 (pt)
CN (1) CN109311889B (pt)
AU (1) AU2017250302B2 (pt)
BR (1) BR112018071184A2 (pt)
CA (1) CA3020870A1 (pt)
CL (1) CL2018002945A1 (pt)
DK (1) DK3442977T3 (pt)
ES (1) ES2957233T3 (pt)
FI (1) FI3442977T3 (pt)
HU (1) HUE063042T2 (pt)
IL (1) IL262345B (pt)
MX (1) MX2018012664A (pt)
PH (1) PH12018502205A1 (pt)
PL (1) PL3442977T3 (pt)
PT (1) PT3442977T (pt)
SG (1) SG11201808907PA (pt)
WO (1) WO2017181117A1 (pt)
ZA (2) ZA201807256B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
MX2015012062A (es) 2013-03-14 2016-05-05 Tolero Pharmaceuticals Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE059041T2 (hu) 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
RU2704112C2 (ru) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
JP6877407B2 (ja) 2015-08-26 2021-05-26 ブループリント メディシンズ コーポレイション Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
CN108473468B (zh) 2015-11-02 2020-06-16 蓝图药品公司 Ret的抑制剂
AR106756A1 (es) 2015-11-19 2018-02-14 Blueprint Medicines Corp Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
WO2019079649A1 (en) * 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
MX2020010417A (es) 2018-04-03 2021-01-08 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CN109456253B (zh) * 2019-01-11 2020-04-07 上海博璞诺科技发展有限公司 一种手性诱导合成(s)-3-(4-溴苯基)-哌啶或其盐的方法
CA3146701A1 (en) * 2019-08-13 2021-02-18 Blueprint Medicines Corporation Salt and crystal forms of an activin receptor-like kinase inhibitor
US20220396576A1 (en) 2019-10-02 2022-12-15 Blueprint Medicines Corporation Process for preparing an activin receptor-like kinase inhibitor
CN110698388A (zh) * 2019-11-01 2020-01-17 暨明医药科技（苏州）有限公司 一种工业化生产(s)-3-(4-溴苯基)哌啶的方法
TW202241437A (zh) * 2020-12-21 2022-11-01 美商百歐克斯製藥公司 口服alk2抑制劑之給藥方案
JP2024502601A (ja) * 2021-01-07 2024-01-22 バイオジェン・エムエイ・インコーポレイテッド Ｔｙｋ２阻害剤
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060114376A (ko) 2004-01-30 2006-11-06 니뽄 다바코 산교 가부시키가이샤 식욕 감퇴 화합물
EP2187883A2 (en) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
JP5805623B2 (ja) * 2009-04-16 2015-11-04 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ キナーゼ阻害剤として使用するためのイミダゾピラジン類
AR077428A1 (es) 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
CN104470523B (zh) * 2012-03-09 2017-07-11 莱西肯医药有限公司 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
CN104583211A (zh) 2012-04-17 2015-04-29 吉里德科学公司 用于抗病毒治疗的化合物和方法
EP2838898B1 (en) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
JP2016510745A (ja) * 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
MX2015012062A (es) * 2013-03-14 2016-05-05 Tolero Pharmaceuticals Inc Inhibidores de jak2 y alk2 y metodos para su uso.
UY35419A (es) 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE059041T2 (hu) 2013-10-17 2022-10-28 Blueprint Medicines Corp Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2704112C2 (ru) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2017106742A (ru) 2014-08-05 2018-09-06 Элиос Биофарма, Инк. Комбинированная терапия для лечения парамиксовируса
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
US10179777B2 (en) 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
JP6877407B2 (ja) 2015-08-26 2021-05-26 ブループリント メディシンズ コーポレイション Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
CN108473468B (zh) 2015-11-02 2020-06-16 蓝图药品公司 Ret的抑制剂
AR106756A1 (es) 2015-11-19 2018-02-14 Blueprint Medicines Corp Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
WO2018064510A1 (en) * 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins

Also Published As

Publication number Publication date
ZA201807256B (en) 2024-02-28
PL3442977T3 (pl) 2024-03-04
US10669277B2 (en) 2020-06-02
US20170298069A1 (en) 2017-10-19
JP7017521B2 (ja) 2022-02-08
KR102426043B1 (ko) 2022-07-27
US11634422B2 (en) 2023-04-25
IL262345B (en) 2022-01-01
PH12018502205A1 (en) 2019-10-28
US20220315585A1 (en) 2022-10-06
AU2017250302A1 (en) 2018-11-22
IL262345A (en) 2018-11-29
DK3442977T3 (da) 2023-10-09
HUE063042T2 (hu) 2023-12-28
JP2019513781A (ja) 2019-05-30
AU2017250302B2 (en) 2021-01-21
ES2957233T3 (es) 2024-01-15
CL2018002945A1 (es) 2019-03-15
CN109311889A (zh) 2019-02-05
CN109311889B (zh) 2021-11-16
EP4285996A3 (en) 2024-01-10
EP3442977B1 (en) 2023-06-28
US10233186B2 (en) 2019-03-19
ZA202005341B (en) 2022-01-26
KR20190005876A (ko) 2019-01-16
US20200031830A1 (en) 2020-01-30
MX2018012664A (es) 2019-03-07
EP3442977A1 (en) 2019-02-20
PT3442977T (pt) 2023-10-04
WO2017181117A1 (en) 2017-10-19
CA3020870A1 (en) 2017-10-19
SG11201808907PA (en) 2018-11-29
EP4285996A2 (en) 2023-12-06
FI3442977T3 (fi) 2023-09-26

Similar Documents

Publication Publication Date Title
BR112018071184A2 (pt) inibidores do receptor de activina tipo quinase
PH12018500907A1 (en) Inhibitors of ret
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
EA201691916A1 (ru) Биарильные ингибиторы киназы
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
CR20190232A (es) DERIVADOS DE TIOHIDANTOÍNA SUSTITUÍDOS COMO ANTAGONISTAS DEL RECEPTOR DE ANDRÓGENOS (divisional 2018-0352)
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
EA201890847A1 (ru) Композиции и способы ингибирования бета-лактамазы
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX2021000895A (es) Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]